Production & Sales

AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy

AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and potential commercialisation of its botensilimab and balstilimab (BOT/BAL) immunotherapy combination programme.

BD invests $110m to expand US prefillable syringe production

BD (Becton, Dickinson and Company) has announced a $110m investment to expand its production of prefillable syringes in the US.

Santhera grants Agamree rights to Nxera for DMD

Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD) in Australia, Japan, New Zealand, and South Korea.

Samsung Bioepis initiates Byooviz commercialisation in Europe

Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in Europe.

Denali makes $275m funding agreement with Royalty Pharma

Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa therapy.

Formosa and Rxilient sign licensing agreement for APP13007

Formosa Pharmaceuticals and Rxilient Medical have signed an exclusive licensing agreement for the commercialisation of Byqlovi, clobetasol propionate ophthalmic suspension, 0.05% (APP13007), in the Association of Southeast Asian Nations (ASEAN) markets.

Corstasis Therapeutics partners CVL for Enbumyst integration

Corstasis Therapeutics has announced a collaboration with Cardiovascular Logistics (CVL) to advance the adoption and integration of Enbumyst nasal spray into heart failure care.

CNX Therapeutics expands CNS portfolio with Sativex acquisition

CNX Therapeutics has acquired Jazz Pharmaceuticals’ global Sativex (nabiximols) business, expanding its central nervous system (CNS) portfolio.